SynAging announces extension of its collaboration with Europe's largest biopharmaceutical company Download PDF
First Commercial in vitro Test System for Human Neuroprotection in Proteopathic Diseases such as Alzheimer’s and Parkinson’s Download PDF
SynAging Expands its Capabilities: Building a New Animal Facility and Hiring a Head of Pharmacology Download PDF, 150 KB
Low Number Aβ Oligomers (Proprietary Preparations)
Toxic Aβ oligomers (AβO) from the following peptide variants have been successfully established and validated in vitro and in vivo:
AβO preparations are used at submicromolar concentrations and largely consist of tetramers, some trimers and residual monomers. They are completely stable when stored frozen. Every preparation is tested before using in client projects.
In vivo AβO are used at a dose of 50 pmol (equivalent to the constituent monomer peptide concentration).